Corpus ID: 8136355

Vitaxin applied molecular evolution.

  title={Vitaxin applied molecular evolution.},
  author={K. Mikecz},
  journal={Current opinion in investigational drugs},
  volume={1 2},
  • K. Mikecz
  • Published 2000
  • Medicine
  • Current opinion in investigational drugs
Vitaxin is a humanized version of LM-609 (an mAb licensed from the Scripps Research Institute and Dr David Cheresh in May 1994, which blocks the integrin receptor, alpha v beta 3) [172038]. It is in phase II trials for the potential treatment of leiomyosarcoma [316471] and is also being studied in phase I trials as an anti-inflammatory and potential rheumatoid arthritis therapy [364031,313665]. Vitaxin and non-peptides are under evaluation for use in the treatment of other diseases in which… Expand
Effects of Vitaxin®, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro
Ligands to the integrin receptor αvβ3
Integrins: Molecular targets in cancer therapy
  • G. Tucker
  • Medicine
  • Current oncology reports
  • 2006
Anti‐angiogenic drugs: from bench to clinical trials